ResearchPod Summary
Broadly neutralizing antibodies (bNAbs) have been considered a major pathway toward an effective HIV-1 vaccine. However, many HIV-1 isolates remain resistant to these antibodies, often requiring high concentrations that are difficult to achieve in vivo. This study investigates eCD4-Ig, an engineered fusion protein designed to improve upon natural bNAbs by more effectively targeting the highly conserved sites of the HIV-1 envelope glycoprotein (Env).
The researchers designed eCD4-Ig by fusing a small CCR5-mimetic sulfopeptide to CD4-Ig. This fusion acts by binding cooperatively and with high avidity to the conserved CD4-binding site and the coreceptor-binding site on the HIV-1 Env trimer. By engaging two conserved sites simultaneously, eCD4-Ig demonstrates vastly improved breadth and potency—neutralizing 100% of tested neutralization-resistant isolates with geometric mean IC50 values far lower than those of standard bNAbs like VRC01 or 3BNC117.
To test clinical viability, the authors used Adeno-associated virus (AAV) vectors to deliver the gene for rhesus eCD4-Ig into macaques. This gene-therapy approach resulted in stable, long-term serum concentrations of the protein. The vaccinated macaques remained resistant to repeated intravenous challenges with SHIV-AD8, a simian-human immunodeficiency virus, whereas control animals became infected. Importantly, eCD4-Ig appeared less immunogenic than standard bNAbs, likely because it possesses fewer non-self B- and T-cell epitopes compared to the highly hypermutated antibody sequences found in current bNAb candidates.
AAV-delivered eCD4-Ig functions as a potent, broad-spectrum prophylactic that essentially acts as an artificial immune system. Its ability to achieve stable expression and provide robust, long-term protection suggests it could overcome the limitations of conventional vaccine strategies, potentially offering a path toward near-universal protection against diverse HIV-1 variants.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.